ProRx, LLC
Outcome
FDA issued a warning letter on March 4, 2025, documenting serious sterility violations at ProRx's 503B outsourcing facility including flying insects in sterile areas, blocked critical airflow, and inadequate gowning; the firm recalled approximately 40,000 vials of compounded semaglutide and tirzepatide in 2024 due to lack of sterility assurance.
Details
ProRx, LLC — 503B Sterility Violations / Compounded GLP-1 Recall (2025)
Outcome: FDA issued a warning letter on March 4, 2025, documenting serious sterility deficiencies at ProRx's outsourcing facility, including insects in sterile areas and blocked critical airflow; the firm had recalled approximately 40,000 vials of compounded semaglutide and tirzepatide in August 2024 due to lack of sterility assurance.
ProRx, LLC operates as a 503B outsourcing facility at 619 Jeffers Circle, Exton, Pennsylvania 19341. As a registered 503B outsourcing facility, ProRx is subject to current Good Manufacturing Practice (CGMP) requirements and must produce sterile drug products under conditions that ensure patient safety. FDA investigators inspected the facility from July 15 to August 2, 2024, and identified serious deficiencies in practices for producing sterile drug products, creating unacceptable patient risk.
Specific violations documented during the inspection included: flying insects observed in sterile manufacturing areas; the Pharmacist-in-Charge observed kneeling on the floor in a cleanroom environment; operators blocking first-pass laminar airflow over uncapped filled vials (a critical sterility breach); inadequate gowning procedures; and a lack of documented protocols to prevent microbial contamination during filling operations. The facility was producing compounded semaglutide (5 mg/2 mL), tirzepatide (60 mg/3 mL), and vancomycin (25 mg/mL), among other products — sterile injectables intended for patient administration.
On August 22, 2024, ProRx initiated a voluntary recall of all sterile drug products within expiry due to lack of sterility assurance. The recall ultimately covered approximately 40,000 vials distributed to Texas and Utah, classified as a Class II recall. The firm ceased sterile production August 7, 2024. FDA issued the formal warning letter on March 4, 2025, requiring comprehensive corrective actions. An additional recall in October 2025 covered further vials. Drug product labels also failed to include required compounding-specific disclosures and ingredient information.
Primary Source: ProRx, LLC - 696742 - 03/04/2025 | FDA
How Crucible Prevents This
A 503B outsourcing facility producing sterile injectables (semaglutide, tirzepatide) faces the highest-stakes CGMP requirements in pharmacy. Crucible's pre-tool-check gate — requiring documented sign-off before any production run — models the same logic as FDA's required batch release protocols. The violations found (blocked laminar airflow, kneeling on sterile floor, flying insects) represent physical process failures that a documented pre-production checklist enforced at every shift would have surfaced long before an FDA inspector arrived.
Don't let this happen to your organization. See how Crucible works.
See How Crucible Works